The U.S. Court of Appeals for the Federal Circuit tossed a $1.2 billion fine against Gilead Sciences after invalidating portions of a Memorial Sloan Kettering Cancer Center patent licensed to a Bristol Myers Squibb subsidiary. The patent was the basis for the previous ruling against Foster City, Calif.–based Gilead, which related to patent infringement claims…